Milan, Italy-headquartered specialty pharmaceutical firm Eurand has provided an update on the status of Zentase (EUR-1008), its lead innovative pancreatic enzyme replacement product candidate being developed to treat pancreatic insufficiency.
While Eurand says it has provided responses to the US Food and Drug Administration's questions outlined in its "approvable letter" relating to the manufacture of the product, the firm's raw material supplier will not be filing its answers to queries over the drug master file for several weeks. As a result, Eurand is revising its guidance for the commercial launch of Zentase from the late fourth quarter of 2008 to the first quarter of 2009.
The product is being developed to treat pancreatic insufficiency, a condition associated with cystic fibrosis, chronic pancreatitis and other diseases. The company plans to market Zentase in the USA and out-license it to potential partners elsewhere.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze